Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | HER2amp | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7527.098 | 0.3379 | 0.0668 | 1.7263 | |
| SK-BR-3 | HER2amp | Luminal | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7527.098 | 0.3170 | 0.0280 | 1.7263 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7528.098 | 1.0039 | 1.0080 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7528.098 | 0.9767 | 0.9520 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7528.098 | 1.0111 | 1.0229 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7528.098 | 1.0193 | 1.0397 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7528.098 | 1.0162 | 1.0334 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 7528.098 | 0.9404 | 0.8775 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 7528.098 | 0.9119 | 0.8189 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 7528.098 | 0.8784 | 0.7502 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 7528.098 | 0.8759 | 0.7450 | 0.9717 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 9044.098 | 0.9674 | 0.9261 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 9044.098 | 1.0233 | 1.0530 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 9044.098 | 0.9661 | 0.9232 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 9044.098 | 0.9721 | 0.9368 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 9044.098 | 0.9927 | 0.9835 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 9044.098 | 0.9494 | 0.8856 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 9044.098 | 0.9110 | 0.7991 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 9044.098 | 0.9390 | 0.8620 | 0.8807 | |
| SUM1315MO2 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 9044.098 | 0.7389 | 0.4184 | 0.8807 | |
| SUM159PT | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 7531.098 | 1.0211 | 1.0120 | 3.4793 | |
| SUM159PT | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 7531.098 | 0.9824 | 0.9898 | 3.4793 | |
| SUM159PT | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 7531.098 | 1.0313 | 1.0178 | 3.4793 | |
| SUM159PT | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 7531.098 | 1.0366 | 1.0208 | 3.4793 | |
| SUM159PT | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 7531.098 | 1.0615 | 1.0346 | 3.4793 |